The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).
 
Pasquale Rescigno
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Janssen; Merck; MSD Italy
Travel, Accommodations, Expenses - AstraZeneca; Ipsen
 
Maria Dolores Fenor de la Maza
Honoraria - Janssen; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche
 
Stephanie M. Burnett
No Relationships to Disclose
 
Guillermo Villacampa
No Relationships to Disclose
 
Morgaine Stiles
No Relationships to Disclose
 
Fay Helen Cafferty
No Relationships to Disclose
 
Nick Beije
No Relationships to Disclose
 
Suzanne Carreira
No Relationships to Disclose
 
Ines Figueiredo
No Relationships to Disclose
 
Penelope Flohr
No Relationships to Disclose
 
Bora Gurel
No Relationships to Disclose
 
Claudia Bertan
No Relationships to Disclose
 
Daniel Westaby
No Relationships to Disclose
 
Khobe Chandran
No Relationships to Disclose
 
Mateus Crespo
No Relationships to Disclose
 
Carla Perna
No Relationships to Disclose
 
Nina Tunariu
No Relationships to Disclose
 
Adam Sharp
Honoraria - Astex Pharmaceuticals; MSD
Consulting or Advisory Role - Charm Therapeutics; D. E. Shaw Research
Travel, Accommodations, Expenses - Nurix; Roche/Genentech; Sanofi
 
Christina Yap
Honoraria - Bayer
Consulting or Advisory Role - Faron Pharmaceuticals
Travel, Accommodations, Expenses - Faron Pharmaceuticals
 
Johann S. De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harpoon (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi